about
Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious DiseasesAntibodies against AT1 receptors are associated with vascular endothelial and smooth muscle function impairment: protective effects of hydroxysafflor yellow ALectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.Structure-based Design Targeted at LOX-1, a Receptor for Oxidized Low-Density Lipoprotein.Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury.Activation of renin-angiotensin system is involved in dyslipidemia-mediated renal injuries in apolipoprotein E knockout mice and HK-2 cellsInteraction of RAS activation and lipid disorders accelerates the progression of glomerulosclerosisAT(2) receptor and tissue injury: therapeutic implications.Endothelium and its alterations in cardiovascular diseases: life style intervention.Reactive oxygen species mediate angiotensin II-induced transcytosis of low-density lipoprotein across endothelial cells.Lectin-like oxidized low-density lipoprotein receptor 1 pathways.LOX-1, a new marker of risk and prognosis in coronary artery disease?LOX-1, OxLDL, and atherosclerosisClinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics.Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way.Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases.LOX-1 deletion limits cardiac angiogenesis in mice given angiotensin II.
P2860
Q28081001-BF5E0E30-8326-40A4-811E-3FB4B253ED48Q28534198-CFA8AE0A-B24D-4DB6-BCF8-0EA3514ACD73Q33564156-2A33E35A-30AB-430A-8ED6-E6303EADF83FQ35844550-A5BEBBB0-66FC-4988-8299-D20F49775DB0Q36727852-0E9DA0BC-1881-43BB-812B-8AE836FDE45AQ36996652-08810114-151F-4F61-B2B2-A9ACF8E46432Q37246055-F4BDC6D9-33D6-47AF-95A0-88FEAD03641FQ37531017-A4BA0702-6040-4D0A-87FC-7A8D10901316Q37639902-6A154314-F301-47D8-AB31-16EC41AA4FC6Q37713975-328DF44F-9832-44D5-A590-8D7E9A8241A2Q38099693-D38230FD-D00C-4828-A64C-A8D951BFF4D4Q38128195-68B68BDC-D2B0-4146-9739-598079E67C24Q38128283-F4A54067-BA26-4C1E-A364-B7FBA05EB2BFQ38589168-5B81C405-6EA1-43B5-98FE-9D0FC33E2016Q41874906-7EC16514-0CB5-4BE4-AE5E-C2E452C544E2Q47682969-C8F24857-D309-45F5-998E-F6BB55D41B43Q48258246-0B20C609-5D7E-4681-9E8A-31FE3958FA0B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
LOX-1 and angiotensin receptors, and their interplay.
@en
LOX-1 and angiotensin receptors, and their interplay.
@nl
type
label
LOX-1 and angiotensin receptors, and their interplay.
@en
LOX-1 and angiotensin receptors, and their interplay.
@nl
prefLabel
LOX-1 and angiotensin receptors, and their interplay.
@en
LOX-1 and angiotensin receptors, and their interplay.
@nl
P2093
P2860
P1476
LOX-1 and angiotensin receptors, and their interplay.
@en
P2093
Jawahar L Mehta
M Ian Phillips
Xianwei Wang
P2860
P304
P356
10.1007/S10557-011-6331-7
P577
2011-10-01T00:00:00Z